Kornimate/medical-research-clean huggingface dataset:
study of zg005 in patients with advanced solid tumors

Conditions: Advanced Solid Tumor

Summary: this is an open-label, multicenter, phase ii clinical trial, designed to evaluate the efficacy and safety of zg005 in patients with advanced solid tumors who have previously failed or are intolerant to standard treatment.


Eligibility criteria:
inclusion criteria: * fully understand the study and voluntarily sign the informed consent form. * male or female 18-75 years of age; * eastern cooperative oncology group (ecog) performance status of 0-1; * life expectancy ≥ 12 weeks; * histologically or cytologically confirmed diagnosis of advanced solid tumors. exclusion criteria: * medical history, computed tomography (ct) or magnetic resonance imaging (mri) results indicate that existence of the central nervous system(cns) metastases; * any other malignancy within 5 years.
nonalcoholic fatty liver disease is associated with increased atrial fibrillation risk in an elderly chinese population

Conditions: Nonalcoholic Fatty Liver Disease; Atrial Fibrillation; Cross-sectional Study

Summary: atrial fibrillation and nonalcoholic fatty liver disease are two pathological conditions that are highly prevalent worldwide and share multiple cvd risk factors. there is rare research performed among elderly adults. the investigators are conducting a cross-sectional analysis of elderly adults (≥65 years) to investigate the association between atrial fibrillation and nonalcoholic fatty liver disease in an elderly chinese population.

because of the aging population and improvements in cardiovascular treatments, its prevalence is expected to increase substantially over the next few decades. af has been reported to be associated with high rates of hospitalization and death. along with older age, there are many independent risk factors for af like obesity, hypertension, diabetes, ischemic heart disease, heart failure and valvular heart disease. non-alcoholic fatty liver disease is one of the most prevalent liver diseases in the world whose prevalence ranges from 6% to 35%, with a median of 20% in the general population. in recent years, an increasing body of evidence have indicated that nafld is linked to cardiovascular disease, myocardial abnormalities, left ventricular diastolic dysfunction, heart failure, aortic valve sclerosis and so on. nafld has also been observed to be significantly associated with af in patients with type 2 diabetes. furthermore, a cohort study showed that nafld was associated with an increased risk of prevalent af in a middle-aged population. however, whether the association between nafld and af also holds true in the elderly population remains uncertain. therefore, the investigators conducted this cross-sectional study to explore the association between nafld and af in an elderly chinese population.

Eligibility criteria:
inclusion criteria: * those who undergone an annual physical examination at zhenhai lianhua hospital, ningbo, china in 2014 * elderly adults (≥65 years old) exclusion criteria: * unknown alcohol intake or excessive alcohol intake * unknown bmi or bmi≤18.0kg/m2 * incomplete basic physical data * missing liver ultrasonic diagnosis * unknown causes of chronic liver disease
assessment of the acute effect of ip

Conditions: Deficiency Growth Hormone

Summary: it is a nutraceutical system, consisting of oral tablet and an oral spray called alpha gpc, which helps your body naturally restore the hgh levels.


Eligibility criteria:
inclusion criteria: * males and females having age between 40-60 years (both inclusive) * bmi ≥25 and ≤29.9 kg/m2 * fbs ≤ 120 mg/dl * serum hgh levels ≤0.94 ng/ml in females and ≤0.12 in males * thyroid stimulating hormone ≥ 0.35 and ≤ 5.55 miu/ml exclusion criteria: * history of thyroid disorder (hyper/hypo). * smokers having at least 1 cigarette per day. * known hypersensitivity or allergy to one or more of the ingredients of the ip * participant suffering from primary or secondary insomnia with/without active treatment. * alcoholics as defined by consumption of more than 2 standard alcoholic drinks (more than 30 ml/ day) for past 3 months.
study evaluating erb-041 in endometriosis in reproductive-age women

Conditions: Endometriosis

Summary: the purpose of this investigational study is to determine if a study medication is safe and effective in reducing the symptoms associated with endometriosis; if the study medication reduces the need for pain medication for endometriosis symptoms; and if the study medication improves a participant's ability to carry out daily activities. qualified participants will receive no cost treatment, which may include study-related examinations, diagnostic procedures including a pap smear, laboratory testing, and a mammogram (aged 40-45). qualified participants will also receive study medication at no cost. as a participant, the study volunteer may also experience the satisfaction of knowing she is helping the advancement of women's health care.


Eligibility criteria:
inclusion criteria: * surgical diagnosis of endometriosis within 5 years * not pregnant and not lactating * willing to use non-hormonal contraception, history of regular menstrual cycles exclusion criteria: * hysterectomy, surgical treatment for endometriosis within 3 months * certain medications for the treatment of endometriosis * previous history of a malignancy * abnormalities on physical or gyn exams and abnormal lab tests

Keywords: endometriosis
radial artery versus saphenous vein patency (rsvp) trial - 10 year follow-up

Conditions: Coronary Artery Disease

Summary: during coronary bypass surgery, veins are taken from the leg and applied to the heart and aorta to 'bypass' narrowings in the coronary arteries. however using an artery in the chest, the internal mammary artery, means that the bypass lasts longer than using veins. the investigators recently showed that using an artery from the arm as a bypass vessel, the radial artery, also had less furring up than veins 5 years after surgery. now the investigators would like to ask patients to come back for an angiogram 10 years following surgery.


Eligibility criteria:
inclusion criteria: * included in the rsvp study * willing to attend for coronary angiography * willing to give written informed consent exclusion criteria: * contraindication to coronary angiography * participation in research project within previous 60 days * unwilling to give written informed consent

Keywords: coronary artery bypass surgery arteries veins conduits
a study of ly900014 (lyumjev) versus insulin lispro (humalog) in participants with type 1 diabetes

Conditions: Diabetes Mellitus, Type 1

Summary: this study will be conducted in participants with type 1 diabetes mellitus on continuous subcutaneous insulin infusion (csii) or pump therapy to evaluate the effect of ly900014 (lyumjev) on blood sugar levels during exercise using different approaches on basal rate reduction and following a test meal compared to insulin lispro (humalog). the study may last up to approximately 10 weeks and may include up to 7 visits.


Eligibility criteria:
inclusion criteria: * male or female participants with type 1 diabetes * body mass index (bmi) between 18.5 and 29.0 kilograms per square meter (kg/m²), inclusive * hemoglobin a1c (hba1c) less than or equal to 8.5 percent (%) * using csii and stable insulin regimen for at least 6 months prior to inclusion into the trial * able to undergo at least 1 hour of moderate-intensity exercise exclusion criteria: * are currently participating or recently participated in a clinical trial or any other type of medical research judged to be incompatible with this study * have a blood loss of more than 500 milliliters (ml) within the last month * have known allergies to insulin lispro, related compounds or any components of the study drug formulation * have previously participated or withdrawn from this study * have or used to have health problems or medical test results that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study * participants who have an abnormal blood pressure and/or pulse rate * participants with clinically significant cardiac or pulmonary disease

Keywords: lyumjev humalog® insulin lispro exercise continuous subcutaneous insulin infusion glycemic control hypoglycemia type 1 diabetes
single dose pharmacology study of dg3173 and octreotide in acromegalic patients.

Conditions: Acromegaly

Summary: the study is designed to investigate the safety, tolerability and efficacy of dg3173 in untreated acromegaly patients. twenty patients received ascending single doses of dg3173 and one dose of octreotide, the current gold standard of medical therapy for acromegaly, with each patient receiving all doses of dg3173 as well as octreotide.


Eligibility criteria:
inclusion criteria: * men, women of non childbearing potential or women of child bearing potential who either abstain from sexual intercourse, have a sterile partner or practice a medically approved double barrier method of contraception * diagnosis of acromegaly of pituitary origin * have age adjusted insulin like growth factor 1 (igf-1) concentrations ≥1.5 times the upper limit of normal range on two consecutive measurements in the 6 months prior to the first dosing day (including the measurement to be made at screening \[visit 2\]) * have a random hgh level of ≥5 µg/l in the 6 months prior to or at screening (visit 2) * have given written informed consent * ability to comply with the requirements of the protocol of the study exclusion criteria: * previous specific treatment for acromegaly in the 6 months prior to screening (visit 2), including somatostatin analogues (ssas), surgery, radiotherapy and pegvisomant * treatment with dopamine agonists in the 3 months prior to screening (visit 2) * uncontrolled hypertension or orthostatic hypotension * type i diabetes mellitus, poorly-controlled type ii diabetes mellitus (glycosylated haemoglobin \[hba1c\]≥7.5%) and patients requiring insulin treatment * gallstones or gravel that could cause biliary obstruction * hyperprolactinaemia * participation in a clinical study within 60 days prior to screening (visit 2) * receipt of blood, blood products or plasma derivatives 60 days prior to screening (visit 2) * pregnancy or lactation * a history of active alcohol abuse or drug addiction * positive viral serology screening result for hepatitis b surface antigen, antibodies to hepatitis c virus, or human immunodeficiency virus type 1 and 2 * evidence or suspicion of tumour expansion * clinically significant abnormality in screening ecg * any clinically significant abnormal laboratory safety test (biochemistry, haematology and dipstick urinalysis) in the opinion of the investigator * any disease which in the investigator's opinion would exclude the patient from the study
the lymphoma and leukemia society amended covid-19 registry

Conditions: Covid19

Summary: the lls covid-19 registry is being amended to invite people who participated in the lls covid-19 registry and did not develop antibodies after receiving a complete covid-19 vaccination, as well as people with blood cancer who did not participate in the initial lls covid-19 registry and also did not develop antibodies after receiving a complete covid-19 vaccination, to participate in this amended lls covid-19 registry.

the results of the leukemia and lymphoma society (lls) covid-19 registry indicate that about twenty-five percent (25%) of people with blood cancer and on immunosuppressants participating in the lls covid-19 registry, who received a complete covid-19 vaccination, did not develop antibodies. the food and drug administration has authorized third doses (boosters) of the pfizer and moderna covid-19 vaccines for people with weakened immune systems, in a bid to bolster their protection against infection as the highly contagious delta variant circulates. the agency will amend the emergency-use authorizations for the two vaccines to allow immunocompromised people to get an additional dose. therefore the lls covid-19 registry is being amended to invite people who participated in the lls covid-19 registry and did not develop antibodies as noted above, as well as people with blood cancer who did not participate in the initial lls covid-19 registry and also did not develop antibodies after receiving a complete covid-19 vaccination, to participate in this amended lls covid-19 registry. using the same design as the initial covid-19 registry (protocol llsc19-001), this amended lls covid-19 registry will determine if people who have decided to receive a booster vaccination, who did not develop antibodies after receiving a complete covid-19 vaccination will develop antibodies after a single dose booster of either the pfizer or moderna covid-19 vaccination.

Eligibility criteria:
inclusion criteria: * people with blood cancer who did not develop antibodies after a complete covid-19 vaccination. exclusion criteria: * people who receiived a complete covid-19 vaccination and did develop antibodies. * people unwilling or unable to receive covid-19 booster.

Keywords: covid-19 booster
the drug -drug interaction of sp2086 and glyburide

Conditions: Type 2 Diabetes

Summary: the purpose of the study is to investigate the potential interaction between sp2086 and glyburide after the singe and multiple oral doses treatment in healthy adult volunteers respectively.

this is an open-label (volunteers will know the names of treatments they are assigned) single-center and cross-over study of sp2086 and glyburide in healthy adult volunteers. all subject were randomized into two groups, and the drugs will be administered according to the ab and ba sequences.the a sequence was that glyburide was taken at 5mg qd dose on days1,4,5,6,7 and 8; sp2086 will be administered orally (by mouth) as 200mg on days 8.the b sequence was that sp2086 was taken at 200mg qd dose on days1,4,5,6,7 and 8; glyburide will be administered orally (by mouth) as 200mg on days 8.

Eligibility criteria:
inclusion criteria: * healthy volunteers with a body mass index(bmi) between 19 and 24 kg/m2 * had signed the informed consent himself or herself. exclusion criteria: * have the abnormal lab or other examination results and the change have clinical significance. * known allergy to sp2086 or glyburide or any of the excipients of the formulation of sp2086 or glyburide. * history of using the sulfa or sulfonylureas or dpp-ivor glp-1 drugs or other similar structure drugs. * history of severe unconsciousness hypoglycemia * history of any surgery prior to screening in 6 months. * history of blood donation≥400 ml prior to screening in 3 months or participate in blood donation,or by blood transfusion in one month. * history of participate any drug or medical device prior to screening in 3 months. * within a month before the screening using any prescription drugs, over-the-counter drugs, chinese herbal medicine (especially oral antidiabetics drugs) or food supplements( vitamins). * 2 days before the randomization ,the patients can not ban alcohol, tobacco, or reference food or drink containing caffeine or xanthine , or vigorous exercise, or there are other factors that can affect drug absorption, distribution, metabolism and excretion. * the hepatitis b surface antigen, hepatitis c antibody, hiv antibody and syphilis antibody was positive. * pregnancy or lactation women, or a fertility male or female is not willing to contraception during test. * researchers considered that there was any situation that may cause the participants can't finish this study or bring any obvious risk to subjects.

Keywords: sp2086 glyburide drug-drug interaction
study to test the effectiveness of a new treatment for scalp psoriasis

Conditions: Psoriasis

Summary: the purpose of this study is to test the effectiveness of dermipsor's dps-102 (test product) in patients with scalp psoroasis. the study is also intended to assess the safety of the product.

psoriasis is a non-contagious skin disorder affecting up to 2% of the world population. it is estimated that 26 million people in the u.s. and europe suffer from psoriasis. forty percent (40%) of these suffer from psoriasis of the scalp. currently, there are three primary modalities for the treatment of psoriasis: topical, phototherapy and systemic treatments. while existing treatments provide varying degrees of relief for this illness, they do not provide a long-term cure. additionally, there is evidence that some of these existing treatments may cause significant side effect. the purpose of this study is to demonstrate that dermipsor's dps-102 (test product) is statistically more effective for the treatment of psoriasis current topical treatment options. it is also intended to assess the safety of dps-102.

Eligibility criteria:
inclusion criteria: * male or female of age 18 or older * patient with a personal history of scalp psoriasis * patient with treatable lesions * patient with a tss score equal or lower than 9. * patient with a pga score equal or lower than 5. * patient with a negative urine pregnancy test at inclusion for women of childbearing potential and using an efficient contraceptive (oral contraceptives, iud, or tubal ligation) * patient agreeing to participate to the study and to sign a written informed consent and comply with study requirements. exclusion criteria: * patient treated with topical scalp treatment for scalp psoriasis within two weeks prior to the inclusion in the study (corticoids, retinoids, vitamin d derivatives), * patient treated with systemic treatment for psoriasis (biologics, methotrexate, cyclosporine, retinoids) within one month prior to the inclusion in the study * patient taking systemic niacin or multivitamins within past two weeks * patient who start or modify a treatment with beta-blockers within one month prior to the inclusion in the study * patient with peg (poly ethylene glycol) allergy * pregnant or breast feeding female or female who do not use contraception, * patient with an history of hypersensitivity to dovonex/daivonex * patient who has participated in a clinical trial within three month prior inclusion, * patients on carbamazepine and primidione (the clearance of primidione and carbamazepine may be reduced with the concomitant use of nicotinamide) * patient who is under guardianship, or unable to understand the information (for linguistic or mental reason), or unwilling to give her/his informed consent to participate in the study

Keywords: psoriasis scalp psoriasis
study to evaluate the effect of different warm-up times of risankizumab autoinjector (ai) on the injection pain experiences in healthy volunteers

Conditions: Healthy Volunteers

Summary: the objective of this study is to assess the impact of different warm-up times of risankizumab autoinjector (ai) on the participant injection site pain experience in healthy adult volunteers.


Eligibility criteria:
inclusion criteria: - body mass index (bmi) is \>= 18.0 to \<= 30.0 kg/m2. exclusion criteria: * any findings in the medical examination that are deviating from normal and judged as clinically relevant by the investigator. * any laboratory value outside the reference range that the investigator considers to be of clinical relevance. * any evidence of a concomitant disease judged as clinically relevant by the investigator. * history of epilepsy, any clinically significant cardiac, respiratory (except mild asthma), renal, hepatic, gastrointestinal, hematologic, or psychiatric disease or disorder, or any other uncontrolled medical illness.

Keywords: risankizumab
face perception and impact of surgical masks in preterm infants

Conditions: Visual Preference With and Without Mask in Term Infant; Visual Preference With and Without Mask in Preterm Infant

Summary: the preferences to masked and unmasked faces is relevant for premature newborns, since covid-19, most of the faces that surround them during their hospitalization are masked. the premask project is a continuation of the infantmask and babymask studies (concerning infant and newborn), by studying the visual preferences to masked and unmasked faces of premature newborns.


Eligibility criteria:
inclusion criteria: * all preterm infants born before 32sa arriving at term (at≥37sa) hospitalized in the neonatology department of the pediatric hospital of grenoble and approaching discharge will be included. of the potential participants meeting the inclusion criteria, those with at least 1 of the following exclusion criteria will not be eligible for inclusion in the study. exclusion criteria: * parents not fluent in french * parents with no social security rights * patient with a syndromic disorder * abnormal neurological examination invasive or non-invasive ventilation at the time of testing of babies requiring, at the time of testing at ≥37sa, non-invasive or invasive ventilatory support as well as labeled syndromic or ophthalmologic disease of prematurity (retinopathies). * infection requiring isolation * ophthalmologic impairment of prematurity (retinopathy)
distress tolerance and buprenorphine

Conditions: Opioid Dependence

Summary: the investigators propose that inability to tolerate the distress of opioid withdrawal and the negative affect associated with early abstinence are key factors in early illicit opioid lapse and subsequent buprenorphine treatment drop-out. our intervention aimed at increasing distress tolerance is designed to increase treatment adherence.


Eligibility criteria:
inclusion criteria: * initiating buprenorphine treatment (which requires meeting current criteria for a dsm-iv diagnosis of opioid dependence) * plan to remain on buprenorphine for at least three months * age between 18 and 65 years * if female of childbearing potential -- must be using adequate contraception (an intrauterine device, oral contraceptive, depot contraceptive, a barrier method "every time," or hysterectomy) as assessed by the study physician * has at least two persons they regularly contact and can provide contact information for them * speaks english sufficiently to understand instructions and assessments. exclusion criteria: * current methadone maintenance treatment program participation * medically necessary prescription opioid treatment (e.g., for chronic pain) * current criteria for a dsm-iv diagnosis of substance dependence for sedative/hypnotic drugs, alcohol, stimulants, cocaine, inhalants, hallucinogens * a diagnosis of organic brain disorder, bipolar disorder, schizophrenia, schizo-affective, schizophreniform, or paranoid disorder, or major depression (subjects who meet criteria for "substance-induced mood disorder," or dysthymia only will not be excluded) * current suicidality on the modified scale for suicidal ideation * use of daily psychotropic, antidepressant, or anxiolytic medication * evidence of neuropsychological dysfunction as assessed by the study physician with confirmation with the folstein mini-mental status examination * anticipated major painful event (significant surgical procedure) in the coming 6 months * probation/parole requirements that might interfere with protocol participation * history of allergic reaction to buprenorphine or naloxone.

Keywords: opioids distress tolerance buprenorphine
influence of 0.75% ropivacaine topicalization on emergence agitation in children

Conditions: Tonsillitis

Summary: emergence agitation (ea) is highly prevalent in children after surgery. risk factors for ea are eye, nose and throat (ent) surgery, preoperative anxiety, postoperative pain. there are several preventive strategies but none of them completely prevent ea. topical application of ropivacaine can reduce post-tonsillectomy pain. therefore, it might reduce the incidence of postoperative ea.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologist physical status class i/ii * tonsillectomy or adenotonsillectomy under general anesthesia exclusion criteria: * obstructive sleep apnea * developmental delay attention deficit hyperactivity disorder, allergy to local anesthetics, convulsion disorder